KPI data tables
CSL operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | Immunoglobulins | Albumin | Haemophilia | Hereditary angioedema | Peri-operative bleeding | Other Behring |
|---|---|---|---|---|---|---|
| FY 2026 | 6,248 | 1,115 | 1,515 | 884 | 834 | 754 |
| FY 2025 | 6,064 | 1,297 | 1,488 | 760 | 913 | 598 |
| FY 2024 | 5,666 | 1,209 | 1,313 | 733 | 1,023 | 625 |
Source: CSL Annual Report 2026 Note 2 operating revenue by product or service category (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2026.pdf): FY 2026 / FY 2025 immunoglobulins 6,248 / 6,064, albumin 1,115 / 1,297, haemophilia 1,515 / 1,488, hereditary angioedema 884 / 760, peri-operative bleeding 834 / 913, other 754 / 598. Annual Report 2025 Note 2 (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2025.pdf) restates FY 2024: immunoglobulins 5,666, albumin 1,209, haemophilia 1,313, hereditary angioedema 733, peri-operative bleeding 1,023, other 625. FY 2026 results presentation Appendix A (https://investors.csl.com/pdf/3d18fc4f-6133-41c7-9188-ec992e930ca3/Platform/ListPage/CSL-Results-Presentation-for-FY2026.pdf) matches the FY 2026 therapy totals.
| Period | IVIG | SCIG |
|---|---|---|
| FY 2026 | 4,081 | 2,167 |
| FY 2025 | 3,986 | 2,078 |
| FY 2024 | 3,705 | 1,961 |
| FY 2023 | 3,028 | 1,647 |
Source: CSL full-year results presentation, Behring revenue-by-therapy-group pies. FY 2026 Appendix A (https://investors.csl.com/pdf/3d18fc4f-6133-41c7-9188-ec992e930ca3/Platform/ListPage/CSL-Results-Presentation-for-FY2026.pdf): IVIG 4,081, SCIG 2,167. FY 2025 (https://investors.csl.com/pdf/c72789c6-778d-4b88-8657-be40cf97e2b3/CSL-Results-Presentation.pdf): IVIG 3,986, SCIG 2,078. FY 2024 (https://investors.csl.com/pdf/78576f85-4598-455b-80c1-16c391c56445/Results-Presentation.pdf?Platform=ListPage): IVIG 3,705, SCIG 1,961. FY 2023 (https://investors.csl.com/pdf/5180b107-7849-4ad4-aeaf-8092e62b4bb6/CSL-Results-Presentation.pdf): IVIG 3,028, SCIG 1,647. Statutory immunoglobulin totals in Annual Report Note 2 match the IVIG plus SCIG sum each year (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2026.pdf).
| Period | CSL Behring | CSL Seqirus | CSL Vifor |
|---|---|---|---|
| FY 2026 | 11,387 | 2,031 | 2,379 |
| FY 2025 | 11,158 | 2,166 | 2,234 |
| FY 2024 | 10,608 | 2,128 | 2,064 |
| FY 2023 | 9,290 | 2,031 | 1,989 |
Source: CSL Annual Report 2026, segment note, total segment revenue (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2026.pdf): FY 2026 / FY 2025 Behring 11,387 / 11,158, Vifor 2,379 / 2,234, Seqirus 2,031 / 2,166, group 15,797 / 15,558. Annual Report 2025 segment note (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2025.pdf) restates FY 2025 / FY 2024. Annual Report 2024 / FY 2024 statutory accounts segment note (https://investors.csl.com/pdf/457c4fdb-099e-4e72-8917-fd3c8c0b4b96/Full-Year-Statutory-Accounts-for-30-June-2024.pdf): FY 2024 / FY 2023 Behring 10,608 / 9,290, Seqirus 2,128 / 2,031, Vifor 2,064 / 1,989, group 14,800 / 13,310. FY 2026 results presentation (18 Aug 2026, https://investors.csl.com/pdf/3d18fc4f-6133-41c7-9188-ec992e930ca3/Platform/ListPage/CSL-Results-Presentation-for-FY2026.pdf) prints the same FY 2026 totals. IR: https://investors.csl.com/investors/financial-results-and-information
| Period | Adjuvanted egg-based (FLUAD) | Cell culture (FLUCELVAX) | Standard egg-based | Pandemic reservation fees | Pre-pandemic sales | Other (including in-license) |
|---|---|---|---|---|---|---|
| FY 2026 | 968 | 503 | 107 | 183 | 61 | 170 |
| FY 2025 | 901 | 474 | 116 | 179 | 197 | 218 |
| FY 2024 | 1,040 | 535 | 140 | 172 | 59 | 122 |
Source: CSL Annual Report 2026 Note 2 (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2026.pdf): FY 2026 / FY 2025 adjuvanted egg-based 968 / 901, cell culture 503 / 474, egg-based 107 / 116, pandemic reservation fees 183 / 179, pre-pandemic sales 61 / 197, other (including in-license) 170 / 218. Annual Report 2025 Note 2 (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2025.pdf) restates FY 2024: adjuvanted 1,040, cell culture 535, egg-based 140, pandemic reservation 172, pre-pandemic 59, other 122. FY 2026 results presentation Appendix B (https://investors.csl.com/pdf/3d18fc4f-6133-41c7-9188-ec992e930ca3/Platform/ListPage/CSL-Results-Presentation-for-FY2026.pdf) prints FLUAD 968, FLUCELVAX 503, egg-based 107, and pandemic reservation fees 183.
| Period | Iron | Nephrology dialysis | Nephrology non-dialysis | Other Vifor |
|---|---|---|---|---|
| FY 2026 | 915 | 1,036 | 330 | 75 |
| FY 2025 | 1,034 | 871 | 267 | 53 |
| FY 2024 | 1,018 | 786 | 200 | 49 |
| FY 2023 | 1,009 | 771 | 136 | 68 |
Source: CSL Annual Report 2026 Note 2 (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2026.pdf): FY 2026 / FY 2025 iron 915 / 1,034, nephrology dialysis 1,036 / 871, nephrology non-dialysis 330 / 267, other 75 / 53. Annual Report 2025 Note 2 (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2025.pdf): FY 2025 / FY 2024 iron 1,034 / 1,018, dialysis 871 / 786, non-dialysis 267 / 200, other 53 / 49. Annual Report 2024 Note 2 (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2024.pdf and https://investors.csl.com/annualreport/2024/118/): FY 2024 / FY 2023 iron 1,018 / 1,009, dialysis 786 / 771, non-dialysis 200 / 136, other 49 / 68. FY 2026 results presentation Appendix B (https://investors.csl.com/pdf/3d18fc4f-6133-41c7-9188-ec992e930ca3/Platform/ListPage/CSL-Results-Presentation-for-FY2026.pdf) prints the same FY 2026 therapy totals for iron, dialysis, and non-dialysis.